KUALA LUMPUR, Aug 21 -- ForDoz Pharma Corporation has entered into an agreement with Lupin, to market and distribute two complex injectable products in an advanced development stage at ForDoz, in the United States (US) and its territories.
According to a statement, the products are in the Oncology and Anti-infective therapeutic areas which upon approval, will provide affordable alternatives to patients and healthcare professionals.
These two licensed products are flagship technology assets among ForDoz complex injectable product pipeline portfolio including liposome, microsphere, emulsion, nanocrystal, control release nanosuspension and micelle.
The products will be manufactured in ForDoz Pharma’s US-based manufacturing site while the India-based Lupin shall be responsible for the commercialisation. The deal terms are confidential.
“ForDoz Pharma is excited to partner our flagship products with Lupin. Lupin’s leadership presence in the US will complement ForDoz’s scientific capability to bring affordable medicines to patients in an efficient manner,” said ForDoz founder and chief executive officer, James He.
ForDoz Pharma Corporation is a privately-owned specialty pharmaceutical company, focusing on development, manufacturing and commercialisation of value-added sterile and complex injectable products.
-- BERNAMA
No comments:
Post a Comment